Mineralys Therapeutics, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026The company raised cash by selling new stock, which funds operations but dilutes existing shareholders' ownership.
The company raised cash by selling new stock, which funds operations but dilutes existing shareholders' ownership.
The company bought out future payments to keep more profit from its drug, reducing costs but spending cash now.
Stockholders approved leadership and the company's financial auditor, ensuring oversight of the business.
Quarterly earnings show how well the company performed; investors use this to judge business health.
Quarterly earnings show how well the company performed; investors use this to judge business health.
Annual results reveal total business performance and financial position; required filing for all public companies.
Stocky reads Mineralys Therapeutics, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Mineralys Therapeutics, Inc.'s most recent tracked filing was a 8-K on 3 Jun 2026: Sells 5.7 million shares for $142.5 million net proceeds.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.